R

RXRX

Recursion Pharmaceuticals, Inc.

5.22

-0.06-1.14%
Pre Market: 5.22  0.00  0.00%04:36 07/16 EDT

Financial Statements

Statement:

Key indicator

Income Statement

Balance Sheet

Cash Flow

Reporting Period:

Accumulated Report

FY

YoY:
FY: Financial Year Annual Report
Q: Quarter is quarterly reports. Q1, Q2, Q3 and Q4 are reports for a single quarter. Q6 and Q9 are accumulated quarterly reports, respectively contain 6 months' reports and 9 months' report.
Item
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Cash from Operating Activities

-359.17M

-287.78M

-83.52M

-158.61M

-45.40M

Net Income

-463.66M

-328.07M

-239.48M

-186.48M

-87.01M

Depreciation/Depletion & Amortization

36.49M

24.40M

11.76M

8.40M

4.44M

Deferred Taxes

--

--

--

--

--

Non-Cash Items

105.99M

66.14M

39.27M

19.77M

6.33M

Changes in Working Capital

-38.00M

-50.26M

104.92M

-306.00K

30.83M

Cash from Investing Activities

260.06M

-10.23M

193.25M

-271.74M

-8.74M

Capital Expenditures

-13.70M

-11.96M

-37.06M

-39.80M

-5.83M

Other Investing Cash Flow Items, Total

273.75M

1.73M

230.31M

-231.95M

-2.91M

Cash from Financing Activities

304.12M

140.13M

154.34M

458.54M

246.13M

Financing Cash Flow Items

--

--

--

0

0

Total Cash Dividends Paid

--

--

--

--

--

Issuance (Retirement) of Stock, Net

308.56M

140.90M

154.44M

471.34M

239.81M

Issuance (Retirement) of Debt, Net

-4.44M

-766.00K

-90.00K

-12.80M

6.32M

Foreign Exchange Effects

-3.41M

188.00K

-307.00K

--

--

Net Change in Cash

201.60M

-157.69M

263.76M

28.18M

192.00M

Cash Interest Paid

--

96.00K

55.00K

680.00K

989.00K

Cash Taxes Paid

--

--

--

--

--